Remember Hydroxychloroquine or HCQ? The drug that the previous POTUS improperly touted; the drug that was rushed by the U.S. Food and Drug Administration (FDA) to Emergency Use Authorization (EUA) only to be later revoked by the agency once a growing consensus deemed the drug not effective and representing adverse event risks for at least certain populations? Remember, the FDA issued a caution against the drug last summer, reporting that there were reports of “serious heart rhythm problems and other safety issues, including blood and lymph system disorders, kidney injuries and liver problems and failure.” However, the drug has been used for malaria and those with lupus for a long time and continues to be used for those purposes. What’s happened to this drug in the context of COVID-19? Did the world stop using it for this new indication? What about HCQ clinical trials involving COVID-19? TrialSite reported back in November 2020 that a major African clinical trial called “ANTICOV” not only featured HCQ as its primary study drug but the announcement emphasized the importance of therapeutic prevention as vaccine coverage will take months or years in many parts of developing Sub-Saharan Africa. Moreover, a review of active HCQ trials involving COVID-19 in Clincaltrials.gov reveals that there are at least 131 clinical trials ongoing. TrialSite surveys reveal that the drug is widely used in Africa, the Middle East, Asia, and even parts of Eastern Europe and Turkey. Why are there still so many studies and actual real-world use of HCQ in relation to COVID-19, when here in the West, it seems banished as a topic associated with COVID-19? A prominent Yale Physician, public health epidemiologist and investigator shares his perspective with the TrialSite Community in a new paper under consideration for peer-review publication. While TrialSite doesn’t take any particular “sides” in the debate about HCQ, this platform most certainly exists as an unbiased and objective forum to introduce, discuss, and debate research.
According to a recent survey written by Dr. Risch, MD, PhD, every one of the now nine (9) studies of high-risk outpatient HCQ studies reveals a significant 2-fold or better risk reduction for hospitalization or mortality. Moreover, the Yale physician and researcher shows in his recent work that numerous systematic case-series studies reveal a solid treatment benefit versus mortality.
Remember Hydroxychloroquine or HCQ? The drug that the previous POTUS improperly touted; the drug that was rushed by the U.S. Food and Drug Administration (FDA) to Emergency Use Authorization (EUA) only to be later revoked by the agency once a growing consensus deemed the drug not effective and representing adverse event risks for at least certain populations? Remember, the FDA issued a caution against the drug last summer, reporting that there were reports of “serious heart rhythm problems and other safety issues, including blood and lymph system disorders, kidney injuries and liver problems and failure.” However, the drug has been used for malaria and those with lupus for a long time and continues to be used for those purposes. What’s happened to this drug in the context of COVID-19? Did the world stop using it for this new indication? What about HCQ clinical trials involving COVID-19? TrialSite reported back in November 2020 that a major African clinical trial called “ANTICOV” not only featured HCQ as its primary study drug but the announcement emphasized the importance of therapeutic prevention as vaccine coverage will take months or years in many parts of developing Sub-Saharan Africa. Moreover, a review of active HCQ trials involving COVID-19 in Clincaltrials.gov reveals that there are at least 131 clinical trials ongoing. TrialSite surveys reveal that the drug is widely used in Africa, the Middle East, Asia, and even parts of Eastern Europe and Turkey. Why are there still so many studies and actual real-world use of HCQ in relation to COVID-19, when here in the West, it seems banished as a topic associated with COVID-19? A prominent Yale Physician, public health epidemiologist and investigator shares his perspective with the TrialSite Community in a new paper under consideration for peer-review publication. While TrialSite doesn’t take any particular “sides” in the debate about HCQ, this platform most certainly exists as an unbiased and objective forum to introduce, discuss, and debate research.
According to a recent survey written by Dr. Risch, MD, PhD, every one of the now nine (9) studies of high-risk outpatient HCQ studies reveals a significant 2-fold or better risk reduction for hospitalization or mortality. Moreover, the Yale physician and researcher shows in his recent work that numerous systematic case-series studies reveal a solid treatment benefit versus mortality.
